Cardiovascular (CV) Risk Evaluation In Type 2 Diabetes Subjects
Completed
- Conditions
- Type 2 Diabetes MellitusCV Risk
- Registration Number
- NCT00648284
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
The primary objective of this study is to assess the total CV risk in patients with type 2 diabetes and also to assess the impact of rosiglitazone in the total CV risk and the parameters of metabolic syndrome.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1100
Inclusion Criteria
Not provided
Exclusion Criteria
- Patients with ALT > 2.5x the normal value
- With heart failure symptoms
- With diagnosis of angina pectoris or stable angina demanding continuous treatment with nitrates
- With recent myocardial infarction (<6 months)
- With severe renal disfunction
- Pregnant or lactating or planned to be pregnant during the study
- Under investigational drug treatment
- Alcoholic or drug abuser
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of rosiglitazone influence cardiovascular risk in type 2 diabetes patients?
How does rosiglitazone compare to other PPAR-gamma agonists in reducing metabolic syndrome parameters in T2DM?
Which biomarkers correlate with cardiovascular risk reduction in NCT00648284 observational study cohort?
What adverse events are associated with rosiglitazone use in Greek T2DM populations and how are they managed?
How do combination therapies involving rosiglitazone impact CV outcomes compared to standard-of-care for type 2 diabetes?